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CAN WE DO BETTER IN MANAGEMENT OF NEUTROPENIC FEVER IN HE-
MATOLOGICAL PATIENTS?
Poire, X., Black, S., Ayala, L., McBride, P., McCall, P., Steinhauer, C.,
Garcia, I., Kline, J.P., Artz, A., Odenike, O., Larson, R.A., Stock, W.,
van Besien, K. The University of Chicago, Chicago, IL
Neutropenic fever (NF) remains a frequent and life-threaten-
ing complication among patients with hematological malignan-
cies. Early observations of rapid deterioration of bacterial
infections in NF patients support the current standard of empir-
ical and prompt administration of antibacterial therapy as soon
as fever developed. Alerted by anecdotal observations of delayed
antibiotic administration in some of our patients, we started in
March 2006 an observational study in 20 randomly collected
NF patients hospitalized in the Bone Marrow Transplantation
Unit. We observed a median time to antibiotics administration
of 3 hours with delays as long as 69 hours. The reasons for de-
lays were mainly due to internal safety policies governing drug
administration. This strict procedure implemented a step by
step process including fever notification by nurses, physician
evaluation, pharmacy delivery and many others steps which gen-
erated underestimated and unexpected delays, and which inter-
fered with rapidity of interventions. Our policy was changed
to include availability of antibiotics on the transplant unit and
immediate administration upon NF. Many other steps were
eliminated from the procedure. We then evaluated 20 patients
in July 2006 and subsequently 10 consecutive patients every 6
months until October 2008. This intervention has been success-
ful and antibiotics are now consistently administered within
60 minutes of fever notification. Severe anaphylactic reactions
or inappropriate use of broadspectrum antibiotics has not been
observed.
Our data show that commonly utilized internal safety policies may
adversely affect the efficacy of treatment interventions and may ulti-
mately impair the safety and efficacy of management of neutropenic
patients.286
COMBINATION OF VORICONAZOLE AND ANIDULAFUNGIN AS PRIMARY
THERAPY IN HEMATOLOGIC PATIENTS
Cetkovsky, P., Kouba, M., Markova, M., Kolar, M., Hricinova, M.,
Mertova, J., Salek, C., Vitek, A., Cermak, J., Soukup, P. Institute of He-
matology and Blood Transfusion, Prague, Czech Republic
Background: Invasive aspergillosis (IA) has been recognized as one
of the leading infection-related cause of death in hematologic pa-
tients (pts). Voriconazole has been approved for primary (first-
line) therapy of IA. However, outcomes remain poor, especially
in hematopoietic stem cell transplant (HSCT) pts. Existing limited
data have documented improved survival rates with the use of com-
bination therapy; the succesfull application of the voriconazole and
echinocandin has also been described. It seems to be rationale to
use combination antifungal therapy at the beginning of fungal com-
plication, because benefits of combination therapy may be underes-
timated if used late in the course of progressive and refractory
fungal infection.
Methods:Authors evaluated the outcomes of eleven pts (7 males and
4 females), aged 45 years (21-59) treated for hematological maligna-
cies (AML, ALL,MDS,HCL,MPS); allogeneic HSCTwas made in
6 pts. Combination therapy consisting of voriconazole and anidula-
fungine was used in 6 pts for probable IA; 5 pts were treated pre-
emptively or empirically.
Results:A favorable response to combination antifungal therapy
was obtained in 7 pts (64%), complete response in 2 and par-
tial in 5 pts; progression was observed in 4 pts (36%). Overall,
the combination therapy was well tolerated, there were no in-
terruptions or reductions of the therapy due to toxicity or side
effects.
Conclusions: Combination of voriconazol and anidulafungin
might be considered preferable first-line therapy for subsets of
hematologic pts.287
SAFETY AND EFFECTIVENESS OF INTRAVENOUS PENTAMIDINE AS A
FIRST LINE PNEUMOCYSTIS JIROVECI PNEUMONIA (PJP) PROPHYLAXIS
IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC
PROGENITOR CELL TRANSPLANT (AHPCT)
Drillon, M.A.1, Chaleff, S.2, Duerst, R.1, Klein-Gitelman, M.3,
Kletzel, M.1 1Northwestern University Feinberg School of Medicine, Chi-
cago, IL; 2Maine Children’s Cancer Program, Scarborough, ME; 3North-
western University Feinberg School of Medicine, Chicago, IL
Pneumocystis jiroveci pneumonia (PJP) is a major cause of mor-
bidity and mortality in immune-compromised patients. Currently,
trimethoprim-sulfamethoxazole (TMP-SMZ) is the preferred first
line agent for PJP prophylaxis but many patients do not tolerate it.
Alternative agents are aerosolized or intravenous pentamidine, dap-
sone, and atovaquone. A retrospective analysis of pediatric patients
undergoing AHPCT who received I.V. pentamidine as PJP prophy-
laxis was undertaken to evaluate I.V pentamidine for its safety and
potential efficacy.
Patients and Methods. The records of 320 pediatric patients
who underwent AHPCT between January 1996 and October
2007 at Children’s Memorial Hospital and received intravenous
pentamidine monthly for PJP prophylaxis were analyzed. Two
hundred twenty-two had malignancies and 98 non-malignant dis-
eases. Pentamidine was administered monthly (4 mg/kg as a 2 hr
infusion) beginning on day –1 and continued through day +180.
Adverse events were categorized as severe if the drug was dis-
continued and mild when the reaction required only premedica-
tion prior to future doses or no changes to administration of
pentamidine.
Results. Patients received an average of 6 doses of IV pentamidine
(range 1-27, median 5). Patients were censored if they succumbed
from complications or relapsed within 6 months of AHPCT. Sixteen
patients experienced 20 adverse effects attributed to intravenous
pentamidine that included localized reaction (n5 2), gastrointestinal
intolerance (n5 6), rash (n5 1), respiratory symptoms (n5 10) and
Systemic (n5 2). Eight patients required discontinuation of IV pent-
amidine due to intolerance after 1-14 doses (median 2). Fifty-four
patients died before day 100, 21 from pulmonary complications. 7
more died of pulmonary complications between day +100
and + 180. None of the 320 patients including those who died from
pulmonary causes developed PCP during the period of prophylaxis
with IV pentamidine.
Conclusion: Intravenous pentamidine appears to be a safe and po-
tentially effective first line prophylactic agent for PJP in pediatric pa-
tients undergoing AHPCT.
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ADEQUACY OF NUTRITIONAL SUPPORT IN PAEDIATRIC BLOOD AND
MARROW TRANSPLANTATION
Cohen, J.E., Maurice, L. Sydney Children’s Hospital, Randwick, NSW,
Australia
Objectives:The use of nutrition support has become standard prac-
tice during paediatric blood and marrow transplantation (BMT).
Despite the importance of nutrition, inadequate nutrition supple-
mentation does occur during this time, though the specifics of this
have not been previously documented.
Method:We completed a retrospective audit of the nutritional sup-
plementation of 34 paediatric patients admitted for either an
Poster Session II S265allogenic or autologous BMT at Sydney Children’s Hospital, Aus-
tralia between February 2002 and December 2004.
Results: 20% of the patients were at risk of malnutrition on ad-
mission. All patients received parenteral nutrition (PN) as their
standard nutritional therapy, which was commenced on a mean
of day + 1 and was infused for an average of 26 days. Our patients
received an average of 79%610.6(40-100%) of estimated energy
requirements from PN. The glucose/amino acid infusion was in-
adequate on 40% of PN days with the main reason due to fluid
overload causing a reduction in infusion rates. The lipid infusion
was inadequate on 60% of PN days mainly due to stoppages
when drugs and/or blood products were infused. The mean per-
centage weight change on discharge was +0.36 4.7%. This had
a large range of between –9.9% to + 7.9% of body weight and
did not appear to relate to adequacy of parenteral nutrition during
transplant. We found that those patients who had weight loss on
discharge had greater number of days off PN prior to discharge
than those with no weight loss. Those patients who received
enteral nutrition (21%) prior to discharge had no weight loss on
discharge.
Conclusion: This study showed that although frequent rate reduc-
tions in nutrition infusions did occur due to fluid overload or drug
incompatibility with PN, patients still received the majority of their
nutritional requirements. Weight loss on discharge from transplant
may be more indicative of the adequacy of oral/enteral nutrition
prior to discharge rather than the adequacy of the nutrition support
during the transplant. Long-term consequences of inadequate nutri-
tion during a BMT as well as nutritional issues post BMT requires
further study.
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H1N1 INFECTION IN STEM CELL TRANSPLANT PATIENTS
Gupta, S.1, Bayer, R.-L.2 1Nalitt Institute of Cancer and Blood Related
Disorders, Staten Island University Hospital, NY; 2Monter Cancer Cen-
ter, North Shore-Long Island Jewish Health System, NY
Influenza A virus can be a significant cause of morbidity and mor-
tality in the general population as well as in immunocompromised
patients.
We present instances where stem cell transplant patients devel-
oped H1N1 infection with encouraging outcomes.
Case 1: A 26 year old male with history of relapsed Hodgkin’s dis-
ease status post autologous peripheral blood stem cell transplant in
December 2008, presented with fever and cough six months after
transplantation. His chest X-ray revealed consolidation and CT
scan of the chest showed ground glass opacities throughout the
lungs. The patient was started on intravenous antibiotics and a respi-
ratory panel was sent. The panel was positive for non-typeable influ-
enza A, indicative of H1N1 infection. The antibiotics were stopped
andOseltamavir was initiated. After 5 days of treatment, the patient’s
symptoms resolved, and his repeat CT scan showed marked resolu-
tion of the ground glass opacities.
Case 2: A 64 year old male patient with history of relapsed, trans-
formed low grade lymphoma, status post unrelated reduced intensity
allogeneic bone marrow transplantation in December 2008, compli-
cated by GVHD, presented in May 2009, with new onset throat dis-
comfort, cough and fever. A respiratory panel was positive for non-
typeable influenza A and CT scan of the chest revealed bilateral
lung consolidation. The patient was started on Oseltamavir, with
complete resolution of symptoms and improved CT findings.
Discussion: In March 2009, the pandemic caused by H1N1 influ-
enza claimed thousands of lives. This strain of virus represents a qua-
druple reassortment of two swine strains, one human strain and one
avian strain.
Although real time PCR is the most sensitive and specific test for
the diagnosis of H1N1, recent CDC guidelines, do not recommend
this test for every presumed case of H1N1 infection. During the
spring of 2009, a diagnosis of H1N1 infection could bemade, if a pa-
tient presented with signs and symptoms of upper or lower respira-
tory tract involvement and if influenza A was identified on
a respiratory panel. Our patients were diagnosed with H1N1 infec-
tion and with the use of Oseltamavir, had complete response and res-
olution of symptoms with minimal morbidity.
Thus we conclude thatH1N1 infectionmay not be associatedwith
significant morbidity and mortality in stem cell transplant patients if
a timely diagnosis is made and treatment is initiated.290
RED CELL CONTENT IN PERIPHERAL HEMATOPOIETIC PROGENITOR
CELL (HPCA) COLLECTIONS FOR TRANSPLANT IN PEDIATRIC PATIENTS.
COMPARISON TO ADULT MATCHED UNRELATED (URD) PERIPHERAL
BLOOD COLLECTIONS. TO DETERMINE THE MAXIMUM ACCEPTABLE
VOLUME OF RED CELLS FOR INFUSION
Villa, M.1, Schneiderman, J.2, Duerst, R.2, Shook, T.1, Collins, J.3,
Meagher, R.1, Kletzel, M.2 1Northwestern Memorial Hospital, Chicago,
IL; 2Northwestern University Feinberg School of Medicine, Chicago, IL;
3Children’s Memorial Hospital, Chicago, IL
We assessed the amount of red cells in peripheral blood collec-
tions from pediatric patients and compare them to adult URD col-
lections.
Twelve pediatric HPCA collections (5 allo and 7 auto) using the
BCT Spectra at Children’s Memorial Hospital were compared to
18 URD collections from multiple institutions received at North-
western Memorial Hospital Cellular Processing Facility (CTPF)
from January to July 2009. Column statistics and t test were per-
formed on Prism software.
The median total product volume collected per harvest of the
URD was 293 ml (range 166-447) mean 299 SEM+ 18 (95% CI
261-337) The median total product volume collected from pediatric
donors was 133 (range 16-299)mean 138 SEM+ 29 (95%CI 75-202)
p\0.0001. The median Hct per collection of the URD was 6.5%
(range 3-17) mean 7.6 SEM +0.8 (95% CI 5.8-9.3) and from the pe-
diatric collections, themedianHct was 9.5% (range 4.0-19)mean 9.6
SEM+ 1.4 (95% CI 6.3-2.7) p5 0.99. The median red cell volume
per collection for the URDs was 24 ml (range 9-46) mean 23
SEM+ 2.3 (95% CI 18-28) while for the pediatric donors, the me-
dian was 8.5 ml (range 4-36) mean 12 SEM +2.4 (95% CI 6.1-
17.0) p5 0.003.
The Hct in URD vs. pediatric collections was not statistically sig-
nificantly different. Since the red cell content is dependent on the to-
tal product volume, the red cell volume was greater in the URD
collections. HPCA infusions.CRA – DATA MANAGEMENT
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CLINICAL IMPACT OF STOMATITIS SEVERE IN PATIENTS RECEIVING
MYELOBLATIVE, NON MYELOABLATIVE AND REDUCED INTENSITY CON-
DITIONING REGIMENS AND HAEMATOPOIETIC PROGENITOR TRANS-
PLANTATION: EXPERIENCE OF SINGLE CENTER
Gomez-Morales, E.1, Azucena, S.-G.2 1ABC Medical Center, Mexico;
2ABC Medical Center, Mexico
Introduction: Stomatitis severe is the mayor limiting dose by pre-
parative regimen in stem cell transplantation reporting percentages
that vary widely (0% to 100%) associated with intensity chemother-
apy but these percentages not are real (0% with minimal intensity
and 100% with myeloablative regimen) and this represent the goal
of this study additional to analyze their clinical impact on another
complications in transplantation field.
Patients and Methods: Observational and transversal study was
made in patients receiving stem cell transplantation since November
2002 to September 2009 in ABC Medical Center Mexico City. All
were older 1 year (female or male). The preparative regimen were
separated intomyeloablative, nonmyeloablative (ormoderate-inten-
sity) and minimal-intensity in relation with CIBMTR criteria. The
presence of erytema, edema, pain, sore throat and ulcerations mouth
after chemotherapy was defined stomatitis and their severity was
graduated with NCTC v3.0 scale (Stomatitis grade 3 y 4 was defined
severe).
Results: 52 patients with medium age 29 years old (range 2-72).
Predominance male (56.6%; ratio M:F 1.4:1). 21 patients received
myeloablative regimen (40.5%), 19 non myeloablative (36.5%) y
12 minimal-intensity (23%). 23 patients presented stomatitis se-
vere (44.23%) predominance in myeloablative regimens (56.52%
vs 30.4% non myeloablative y 13% minimal intensity) and alloge-
neic transplantation (60.86%). 65.2% of cases with stomatitis
grade 3 required opiates infusion and 100% total parenteral nu-
trition (independently preparative regimen). The febrile
